Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.
P/E ratio for Aileron Therapeutics, Inc. (ALRN)
P/E ratio as of 2023: -0.89
According to Aileron Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.89. At the end of 2022 the company had a P/E ratio of -0.40.
P/E ratio history for Aileron Therapeutics, Inc. from 2013 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -0.89 |
| 2022 | -0.40 |
| 2021 | -1.94 |
| 2020 | -1.66 |
| 2019 | -0.49 |
| 2018 | -0.39 |
| 2017 | -3.47 |
| 2016 | -6.50 |
| 2015 | -9.15 |
| 2014 | -0.26 |
| 2013 | 21.15 |